Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

EV/EBIT
Enterprise Value to EBIT

-1.4
Current
-1.9
Median
4.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1.4
=
Enterprise Value
273m SEK
/
EBIT
-199m SEK
All Countries
Close
Market Cap EV/EBIT
SE
Cantargia AB
STO:CANTA
332.8m SEK -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 18
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
34.5B EUR -76.2
EBIT Growth
SE
Cantargia AB
STO:CANTA
Average EV/EBIT: 22.5
Negative Multiple: -1.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.5
2-Years Forward
EV/EBIT
-5.6
3-Years Forward
EV/EBIT
-1.2

See Also

Discover More